Tag: Adcetris combination regimen

Home / Adcetris combination regimen

Categories

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab produc...
adcetris-combination-regimen

Scan the code